161 related articles for article (PubMed ID: 37013921)
1. More immunosuppressive, more immunotherapy responsive? A double-edged sword of HBV-induced immune response in HCC.
Huang CH; Hsieh SY
Hepatology; 2023 Sep; 78(3):706-708. PubMed ID: 37013921
[No Abstract] [Full Text] [Related]
2. Anti-PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection-Related Advanced Hepatocellular Carcinoma: A Literature Review.
Li B; Yan C; Zhu J; Chen X; Fu Q; Zhang H; Tong Z; Liu L; Zheng Y; Zhao P; Jiang W; Fang W
Front Immunol; 2020; 11():1037. PubMed ID: 32547550
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy of HBV-related advanced hepatocellular carcinoma with short-term HBV-specific TCR expressed T cells: results of dose escalation, phase I trial.
Meng F; Zhao J; Tan AT; Hu W; Wang SY; Jin J; Wu J; Li Y; Shi L; Fu JL; Yu S; Shen Y; Liu L; Luan J; Shi M; Xie Y; Zhou CB; Wong RW; Lu-En W; Koh S; Bertoletti A; Wang T; Zhang JY; Wang FS
Hepatol Int; 2021 Dec; 15(6):1402-1412. PubMed ID: 34850325
[TBL] [Abstract][Full Text] [Related]
4. BMP9-induced vascular normalisation improves the efficacy of immunotherapy against hepatitis B virus-associated hepatocellular carcinoma.
Han Y; Pan Q; Guo Z; Du Y; Zhang Y; Liu Y; Zhao J; Xu J; Yang J; Ouyang D; Tang Y; Wang Q; Li Y; He J; Yang M; Chen H; Yang C; Yang X; You J; Chen Y; Ren M; Zhu Y; Xia J; Xiang T
Clin Transl Med; 2023 May; 13(5):e1247. PubMed ID: 37132170
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient.
Qasim W; Brunetto M; Gehring AJ; Xue SA; Schurich A; Khakpoor A; Zhan H; Ciccorossi P; Gilmour K; Cavallone D; Moriconi F; Farzhenah F; Mazzoni A; Chan L; Morris E; Thrasher A; Maini MK; Bonino F; Stauss H; Bertoletti A
J Hepatol; 2015 Feb; 62(2):486-91. PubMed ID: 25308176
[TBL] [Abstract][Full Text] [Related]
6. Use of Expression Profiles of HBV-DNA Integrated Into Genomes of Hepatocellular Carcinoma Cells to Select T Cells for Immunotherapy.
Tan AT; Yang N; Lee Krishnamoorthy T; Oei V; Chua A; Zhao X; Tan HS; Chia A; Le Bert N; Low D; Tan HK; Kumar R; Irani FG; Ho ZZ; Zhang Q; Guccione E; Wai LE; Koh S; Hwang W; Chow WC; Bertoletti A
Gastroenterology; 2019 May; 156(6):1862-1876.e9. PubMed ID: 30711630
[TBL] [Abstract][Full Text] [Related]
7. ARID1A deficiency promotes progression and potentiates therapeutic antitumour immunity in hepatitis B virus-related hepatocellular carcinoma.
Xing T; Li L; Rao X; Zhao J; Chen Y; Ju G; Xu Y; Gao X; Dong G; Xia X; Guan Y; Zhang L; Wen Z; Liang J
BMC Gastroenterol; 2024 Jan; 24(1):11. PubMed ID: 38166741
[TBL] [Abstract][Full Text] [Related]
8. HBV induced hepatocellular carcinoma and related potential immunotherapy.
Jia L; Gao Y; He Y; Hooper JD; Yang P
Pharmacol Res; 2020 Sep; 159():104992. PubMed ID: 32505833
[TBL] [Abstract][Full Text] [Related]
9. Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy.
Sun C; Sun HY; Xiao WH; Zhang C; Tian ZG
Acta Pharmacol Sin; 2015 Oct; 36(10):1191-9. PubMed ID: 26073325
[TBL] [Abstract][Full Text] [Related]
10. Establishment of nucleic acid sensing pathways-based model in predicting response to immunotherapy and targeted drug in hepatitis virus-related hepatocellular carcinoma.
Peng X; Shi Y; Zhang B; Xu C; Lang J
J Med Virol; 2023 Sep; 95(9):e29084. PubMed ID: 37721443
[TBL] [Abstract][Full Text] [Related]
11. Impact of antiviral therapy on post-hepatectomy outcome for hepatitis B-related hepatocellular carcinoma.
Chong CC; Wong GL; Lai PB
World J Gastroenterol; 2014 May; 20(20):6006-12. PubMed ID: 24876723
[TBL] [Abstract][Full Text] [Related]
12. Identification of cell senescence molecular subtypes in prediction of the prognosis and immunotherapy of hepatitis B virus-related hepatocellular carcinoma.
Yu X; Chen P; Yi W; Ruan W; Xiong X
Front Immunol; 2022; 13():1029872. PubMed ID: 36275676
[TBL] [Abstract][Full Text] [Related]
13. Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma.
Lim CJ; Lee YH; Pan L; Lai L; Chua C; Wasser M; Lim TKH; Yeong J; Toh HC; Lee SY; Chan CY; Goh BK; Chung A; Heikenwälder M; Ng IO; Chow P; Albani S; Chew V
Gut; 2019 May; 68(5):916-927. PubMed ID: 29970455
[TBL] [Abstract][Full Text] [Related]
14. Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma.
Han X; Gu YK; Li SL; Chen H; Chen MS; Cai QQ; Deng HX; Zuo MX; Huang JH
J Cancer Res Clin Oncol; 2019 Feb; 145(2):303-312. PubMed ID: 30267213
[TBL] [Abstract][Full Text] [Related]
15. Peripheral immune characteristics of hepatitis B virus-related hepatocellular carcinoma.
Sun R; Li J; Lin X; Yang Y; Liu B; Lan T; Xiao S; Deng A; Yin Z; Xu Y; Xiang Z; Wu B
Front Immunol; 2023; 14():1079495. PubMed ID: 37077908
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis B viral load affects prognosis of hepatocellular carcinoma.
Yu SJ; Kim YJ
World J Gastroenterol; 2014 Sep; 20(34):12039-44. PubMed ID: 25232241
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of active specific immunotherapy with autologous dendritic cells pulsed with autologous irradiated tumor stem cells in hepatitis B-positive patients with hepatocellular carcinoma.
Wang X; Bayer ME; Chen X; Fredrickson C; Cornforth AN; Liang G; Cannon J; He J; Fu Q; Liu J; Nistor GI; Cao W; Chen C; Dillman RO
J Surg Oncol; 2015 Jun; 111(7):862-7. PubMed ID: 25873455
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis B virus mutation may play a role in hepatocellular carcinoma recurrence: A systematic review and meta-regression analysis.
Zhou HY; Luo Y; Chen WD; Gong GZ
J Gastroenterol Hepatol; 2015 Jun; 30(6):977-83. PubMed ID: 25689418
[TBL] [Abstract][Full Text] [Related]
19. Can Toll-Like Receptor (TLR) 2 be considered as a new target for immunotherapy against hepatitis B infection?
Bagheri V; Askari A; Arababadi MK; Kennedy D
Hum Immunol; 2014 Jun; 75(6):549-54. PubMed ID: 24530748
[TBL] [Abstract][Full Text] [Related]
20. MicroRNAs as therapeutic strategy for hepatitis B virus-associated hepatocellular carcinoma: current status and future prospects.
Tan YL; Chen WN
World J Gastroenterol; 2014 May; 20(20):5973-86. PubMed ID: 24876720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]